Ascendiant Capital Markets Weighs in on Aclarion Q2 Earnings

Aclarion, Inc. (NASDAQ:ACON) – Analysts at Ascendiant Capital Markets reduced their Q2 2026 EPS estimates for Aclarion in a research note issued to investors on Thursday, May 28th. Ascendiant Capital Markets analyst L. Ward now anticipates that the company will post earnings of ($1.05) per share for the quarter, down from their prior forecast of ($0.95). Ascendiant Capital Markets currently has a “Buy” rating and a $7.50 target price on the stock. The consensus estimate for Aclarion’s current full-year earnings is ($4.37) per share. Ascendiant Capital Markets also issued estimates for Aclarion’s Q3 2026 earnings at ($1.05) EPS and FY2026 earnings at ($4.51) EPS.

A number of other equities analysts have also weighed in on the stock. Weiss Ratings upgraded shares of Aclarion from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. Wall Street Zen upgraded shares of Aclarion from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $7.50.

Aclarion Stock Up 0.1%

ACON stock opened at $3.50 on Thursday. The stock has a market capitalization of $8.61 million, a P/E ratio of -0.39 and a beta of 1.22. Aclarion has a 52 week low of $2.34 and a 52 week high of $12.03. The firm has a 50-day simple moving average of $3.31 and a 200-day simple moving average of $4.02.

Aclarion (NASDAQ:ACON) last released its earnings results on Wednesday, May 13th. The company reported ($1.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.21. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.03 million. Aclarion had a negative net margin of 10,320.51% and a negative return on equity of 54.41%.

Aclarion declared that its board has authorized a stock repurchase plan on Wednesday, April 22nd that permits the company to repurchase $2.50 million in outstanding shares. This repurchase authorization permits the company to purchase up to 31% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Aclarion News Summary

Here are the key news stories impacting Aclarion this week:

• Positive Sentiment: Aclarion expanded Nociscan’s reach by partnering with the Institute of Neuro Innovation in Los Angeles, which could increase clinical usage and improve the company’s commercialization prospects. Article Title
• Positive Sentiment: The collaboration is designed to build real-world evidence for Nociscan, which may strengthen adoption among physicians, payers, and providers over time. Article Title
• Neutral Sentiment: Ascendiant Capital Markets kept a Buy rating and $7.50 target, but trimmed near-term and FY2026 EPS estimates, signaling ongoing losses even as it remains constructive on the stock. Article Title
• Negative Sentiment: Analysts’ lowered EPS forecasts for Q2 2026, Q3 2026, and FY2026 highlight that Aclarion is still expected to post meaningful losses, which can temper enthusiasm. Article Title

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.